Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a presentation at the 2021 CMHC Spring meeting, offers a concise overview of recent trials and developments in antithrombotic and antiplatelet therapy in high-risk cardiometabolic patients with coronary artery disease (CAD) or peripheral artery disease (PAD). 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Several cardiometabolic comorbidities, including overweight/obesity, dyslipidemia, cardiovascular diseases, hypertension, and type 2 diabetes or insulin resistance, are common in patients with narcolepsy.  Often these disorders are overlooked, but they have important implications in the management of  these patients.  Some medications used to treat symptoms of narcolepsy may have potential negative effects on cardiovascular health, including in patients that are sensitive to sodium, such as those with hypertension, heart failure, or impaired renal function.  However, long-term data on the c
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a presentation at the 2021 CMHC Spring meeting, offers an overview of insulin pumps and insulin delivery systems for T2DM, as well as expert feedback and practical strategies on how to integrate them to patient care.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Within the past decade, aesthetic medicine –particularly minimally invasive aesthetic practice – has significantly advanced. An increasingly common cultural emphasis on beauty and health has resulted in a surge in anti-aging technologies, minimally invasive aesthetic procedures and cosmeceuticals aimed at helping individuals achieve sprightly appearances with healthy skin.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008). The incidence of AD in industrialized nations has increased by 2- to 3-fold over 30 years– it is estimated to affect between 15% and 30% of children in industrialized nations and up to 10% of adults (Bieber 2010; Silverberg 2013).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
By now, it is established that the burden of cardiometabolic risk, including CVD, diabetes, atherosclerosis, hypertension, obesity, and more, are higher in certain racial and ethnic minorities, including African Americans, Latinos, and Native Americans. As such, it is by no means a coincidence that the burden of COVID-19 morbidity and mortality is disproportionate towards these communities, stemming not only from a higher prevalence of these comorbidities, but also from socioeconomic factors.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
The global epidemic of cardiometabolic disease demands the continual refinement of cardiometabolic care approaches and strategies. As the nation’s premier event in cardiometabolic medicine, the 16th Annual Cardiometabolic Health Congresshas been curated by the field’s leading experts to deliver to you the latest evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
The increasing incidence of atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions. However, the treatment of AD is a clinical challenge.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Patients with a recent myocardial infarction (MI) are classified as very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events according to current guidelines, however, targeted LDL-C achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. For example, recent numbers from the GOULD registry, have shown that <40% of patients with a prior MI were on optimal LLT at enrollment, and only 13.2% had lipid therapy intensified.

Pages